Purpose The aim of this prospective cohort study was to analyze psychotropic drug use in community-dwelling elderly people over a 3-year period and characterize those individuals most susceptible to persistent and incident use.
Introduction
Psychotropic drugs are extensively used by the elderly [1] [2] [3] . In Finland, more than one-third of community-dwelling people aged≥75 years use at least one psychotropic drug [2] . A major concern surrounding psychotropic drug use is the potential for unfavorable outcomes. Specifically, the use of benzodiazepines, antidepressants and antipsychotics has been associated with an increased risk of falls [4, 5] . Other concerns related to benzodiazepine use include dependence [6] and cognitive decline [7] . Moreover, the use of antipsychotics may increase mortality among elderly people with dementia [8, 9] .
In general, psychotropic drugs are recommended to be used for a limited period of time in the elderly. Specifically, benzodiazepines should not be used for longer than 2-4 weeks [6] and antidepressant use should be discontinued 12 months after achieving remission from depression [10] . Furthermore, periodic attempts to reduce or discontinue antipsychotic use are suggested in people with dementia [11] . However, extended periods of psychotropic drug use are indicated in certain psychiatric disorders, such as schizophrenia [12] and recurrent major depression [10] .
Although the guidelines recommend limited duration, several studies indicate that psychotropic drugs are frequently used for extended periods, particularly among elderly people [13] [14] [15] [16] . The occurrence of use deemed as persistent ranges from 4.5 to 21.5% in the general elderly population [17] [18] [19] [20] [21] [22] [23] [24] and from 39 to 70% in elderly users of psychotropic drugs [17, 20, 21, [23] [24] [25] . In addition to differences in the study populations and drugs considered, heterogeneity may result from variations in the definition (from 90 days up to 6 years) and the method of assessment of persistent use (retrospective self-reports, consecutive interviews, pharmacy claims databases).
The identification of characteristics associated with persistent use of psychotropic drugs would aid health care professionals to recognize high-risk patients. Since new users frequently end up as persistent users [26] , the characteristics related to incident use also need to be specified. Although several studies have investigated the occurrence and determinants of persistent and incident use of psychotropic drugs among elderly people [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , few have considered drugs other than benzodiazepines [17, 24] or focused on people aged≥75 years [19] . In addition, the majority of the studies were conducted in the 1980s or early 1990s [17-21, 27, 28] , and some follow-up studies analyzed only those surviving until the end of the follow-up [19, 24] , potentially excluding those with the highest risk for persistent and incident use. The aim of this prospective cohort study was to analyze psychotropic drug use over a 3-year period in community-dwelling individuals aged≥75 years. The study also characterized those individuals most susceptible to persistent and incident use.
Methods

Study population
This study was based on the data collected from the population-based GeMS (Geriatric Multidisciplinary Strategy for the Good Care for the Elderly) intervention study. Initially, a random sample of 1000 persons aged≥75 years (born before 1 November 1928) living in the City of Kuopio, Finland was selected from the census data of the City of Kuopio. These persons were randomly assigned to intervention (n=500) and control (n= 500) groups. The baseline examination was performed in 2004, with follow-ups in three consecutive years (2005, 2006, 2007) . Of the initial sample, 162 refused to participate, two had moved, 81 lived in institutional settings and 55 died before baseline. The remaining 700 community-dwelling participants were included in the analysis. During the study period, 119 participants were lost to follow-up because of death (n=100), refusal (n=17), moving (n=1) or loss of contact (n=1).
Data collection
The study protocol has been described in detail elsewhere [29] . Briefly, the participants of the intervention group underwent a comprehensive geriatric assessment (CGA) at the baseline (2004) and in the 1-year (2005) and 2-year (2006) follow-ups. The CGA included a clinical examination, medication assessment and interventions to improve nutritional state and functional capacity by a team of two physicians (trainees in geriatrics), three study nurses, two physiotherapists and a nutritionist. In addition to the CGA, the participants in the intervention and control groups were interviewed annually (2004) (2005) (2006) (2007) by three study nurses to assess demographic characteristics, health status, cognition, functional capacity and drug use.
The study nurses interviewed the participants either in a municipal health center or at participants' homes, using a structured questionnaire. The Mini-Mental State Examination (MMSE) was used to assess cognitive performance [30] . The Geriatric Depression Scale (GDS15) was employed as a screening instrument for depressive symptoms [31] . Limitations in instrumental activities of daily living (IADL) were screened by the scale developed by Lawton and Brody [32] . Years of education, living situation (alone, with someone), self-rated health (good, fairly good, moderate, fairly poor, poor), self-rated life satisfaction (very satisfied, satisfied, unsatisfied, very unsatisfied) and num-ber of visits to physician during the year preceding the baseline interview were self-reported by the participants. Information on history of psychosis was based on the medical records of the municipal health center and participants' own report. If the participant was unable to answer (e.g. due to dementia), a caregiver or home nursing staff responded instead.
During the annual interviews (2004) (2005) (2006) (2007) carried out by the study nurses, the participants were asked to specify all of the prescription and over-the-counter drugs they were currently taking. On each occasion, the information was confirmed from prescriptions, drug packages and medical records of the municipal health center. Drugs used daily, several times a week or at regular intervals (e.g. long-acting injectable antipsychotics) were defined as regular drugs, while other drugs were considered to be "as needed" drugs. All drugs were coded according to the Anatomical Therapeutic Chemical (ATC) classification system recommended by World Health Organization [33] .
Psychotropic drugs
In this study, psychotropic drugs were defined as antipsychotics (N05A), benzodiazepines (N05B, N05C excluding buspirone, hydroxyzine, valerian and melatonin) and antidepressants (N06A, N06CA01) according to the ATC-classification [33] . A user of a psychotropic drug refers to a participant who was using at least one psychotropic drug either regularly or "as needed" based on the data collected by the study nurses.
Statistical analyses
Characteristics of users and nonusers of psychotropic drugs at baseline were compared using the Pearson χ 2 test for categorical variables and the Mann-Whitney U test for continuous variables. Baseline characteristics associated with persistent (event: discontinuation) and incident use of psychotropic drugs were identified among 700 communitydwelling participants using Cox proportional-hazards regression. Discontinuation occurred when a baseline user did not report any use of psychotropic drugs in a follow-up, whereas initiation occurred when a baseline nonuser reported any use of psychotropic drugs in a follow-up. Survival time was censored at the end of 2007 for participants who did not experience the event during the study period. For the participants who were lost to followup without experiencing the event (n=48 in discontinuation analysis and n=55 in initiation analysis), the survival time was censored at the end of the loss year. The most important reason for loss to follow-up was death in both analyses (88 and 78% of those lost to follow-up, respectively). Psychotropic drugs were analyzed together because of the high frequency of concomitant use (e.g. benzodiazepine and antidepressant) and switching between therapeutic categories (e.g. from benzodiazepine to antipsychotic).
The baseline characteristics included in the Cox proportional-hazards regression analyses are presented in Table 1 . A threshold of≤24 for MMSE scores was used to define cognitive decline and a threshold of≤6 for IADL scores to indicate impairment. Self-rated health was dichotomized into good (includes good and fairly good) and moderate/poor (includes moderate, fairly poor and poor). Self-rated life satisfaction was divided into excellent (includes very satisfied) and moderate/poor (includes satisfied, unsatisfied and very unsatisfied). The number of non-psychotropic drugs included both regularly and "as needed" taken drugs. Age and GDS15 scores were treated as continuous variables. History of psychosis was not included in the analyses because of the low number of participants affected (n = 20). The participants of the intervention and control groups were analyzed together because the group assignment was not associated with discontinuation of psychotropic drug use [hazard ration (HR) 1.09, 95% confidence interval (CI) 0.65-1.82] nor with the initiation of use (HR 0.90, 95% CI 0.59-1.36). In addition, the intervention had minor effects on the prevalence of use of antipsychotics, benzodiazepines and antidepressants [29] . Nevertheless, group assignment was included in the models as a design variable.
Both crude and adjusted Cox proportional-hazards regression analyses were performed. The proportional-hazards assumption for each categorical variable was evaluated by comparing adjusted survival curves between categories. Participants with missing data on any of the chosen variables were excluded from the analyses. However, missing GDS15 scores were imputed with the mean value for the whole study population. Data management and statistical analyses were performed using Statistical Package for Social Sciences (SPSS), ver. 14.0 (SPSS, Chicago, IL).
Ethical issues
Written informed consent was obtained from the participants or their family members or their caregivers. The study protocol was approved by the Research Ethics Committee of the Hospital District of Northern Savo as required by the Finnish legislation.
Results
Psychotropic drug use at baseline
At baseline, 38% (n=269) of the community-dwelling participants used at least one psychotropic drug, with the majority (68%, n=183) using psychotropic drugs on a regular basis. Benzodiazepines were the most commonly used category (31%, n=219), followed by antidepressants (12%, n=83) and antipsychotics (6%, n=40). One in three users of psychotropic drugs (28%, n=76) used at least two psychotropic drugs.
Compared with the nonusers, the users of psychotropic drugs were older, more commonly women and lived more commonly alone (Table 1) . The users and nonusers also differed in terms of health status, cognition, functional capacity and drug use. Of the users of psychotropic drugs, 19 had a history of psychosis of the following types: schizophrenic (n=6), paranoid (n=7), depressive (n=4), reactive (n=1) and unclassified (n=1).
Persistent use of psychotropic drugs
Of the baseline users of psychotropic drugs (n=269), 60% (n=162) reported use in all three follow-ups ( Table 2 ). The majority of these persistent users had a regular pattern of use at baseline (n=120) and in each of the three follow-ups (n=126, 130 and 135, respectively). Over half (n = 85) of the persistent users reported use of at least two therapeutic categories during the follow-up, either in the same year (concomitant use) or in different years (switch between therapeutic categories). Of the persistent users of psychotropic drugs, 8% (n=13) had a history of psychosis, 14% (n=22) had GDS15 scores≥5 and 27% (n=43) had MMSE scores≤24. When the baseline users of antipsychotics, antidepressants and benzodiazepines were analyzed separately, 43, 51 and 55% respectively, reported use in all three follow-ups (Table 3) .
Of the baseline users of psychotropic drugs (n=269), 22% (n=59) discontinued all use of psychotropic drugs during the follow-up (Table 2 ). In adjusted Cox proportional-hazards regression analysis, the oldest individuals, users of at least two psychotropic drugs, regular users of psychotropic drugs and individuals with a good self-rated health were less likely to discontinue use (Table 4) , representing the characteristics associated with persistent use. HRs were materially the same (differed by <10% from the reported HR) after the variables number of psychotropic drugs and pattern of psychotropic drug use had been removed from the model, with the exception of those for education (HR 1.36, 95% CI 0.77-2.41), number of non-psychotropic drugs≥9 (HR1.13, 95% CI 0.61-2.08), MMSE scores≤24 (HR 0.96, 95% CI 0.44-2.09) and IADL scores≤6 (HR 0.85, 95% CI 0.42-1.72).
Incident use of psychotropic drugs
Among the baseline nonusers of psychotropic drugs (n=431), 20% (n=88) initiated psychotropic drug use during the follow-up (Table 2) . Of the initiated drugs, the majority were benzodiazepines (n=44), followed by antidepressants (n= 22) and antipsychotics (n=8). In addition, 14 participants initiated psychotropic drugs from at least two therapeutic categories (e.g. benzodiazepine and antipsychotic). When the baseline nonusers of antipsychotics, antidepressants and benzodiazepines were analyzed separately, 7, 10 and 17%, respectively, initiated use during the follow-up (Table 3) .
In the adjusted Cox proportional-hazards regression analysis, characteristics associated with incident use of psychotropic drugs included increasing GDS15 scores, MMSE score≤24, number of visits to physician≥6, moderate/poor self-rated health, and moderate/poor life satisfaction (Table 5 ).
Discussion
The results of this study show a high prevalence of psychotropic drug use among the community-dwelling individuals aged≥75 years. Despite an increasing awareness of potential adverse effects and the guidelines recommending limited duration, psychotropic drugs were frequently used for extended periods. Specifically, 60% of the baseline users of psychotropic drugs reported use in the 3 following years. In addition, every fifth baseline nonuser initiated psychotropic drug use during the study period, the majority of whom also reported use in the next follow-up. Extended periods of psychotropic drug use are indicated in certain psychiatric disorders. More precisely, life-long Loss=Lost to follow-up because of death, refusal, moving or loss of contact antipsychotic therapy is suggested for patients with schizophrenia and delusional disorder [12] . At least 3 years of antidepressant therapy is recommended for patients with recurrent major depression [10] . In addition, extended periods of antidepressant therapy may be necessary to prevent recurrence among patients with panic disorder, generalized anxiety disorder or obsessive compulsive disorder [34, 35] . However, among our study cohort, persistent use of psychotropic drugs consisted more of benzodiazepines than antipsychotics and antidepressants. Specifically, every fifth Participants with missing data on any of the chosen variables were excluded from the analyses (n=23). Missing GDS15 scores were imputed with the mean value for the whole study population a Cox proportional-hazards regression (adjusted for group assignment)
b Cox proportional-hazards regression (adjusted for group assignment and the other variables listed in the community-dwelling participant used benzodiazepines during the whole study period. This finding is of concern since benzodiazepines should not be used for longer than 2-4 weeks by elderly people because of adverse effects, dependency and limited efficacy in continuous use [6] . Persistent use of psychotropic drugs was specifically associated with the use of at least two psychotropic drugs and a regular pattern of use. The HRs were materially the same after adjusting for several factors reflecting poor mental and general health, suggesting that the associations were not confounded by participants' health status. Moreover, the findings are consistent with those reported previously. More specifically, extended periods of benzodiazepine use have been reported among people with more than one benzodiazepine and among people with a frequent/daily pattern of use [14, 36] . Therefore, the risk for persistent use needs to be considered before an additional psychotropic drug is prescribed to an elderly person. Moreover, recommendations to avoid regular use of benzodiazepines [6] should be strongly emphasized when the aim is to decrease the risk for persistent use.
Consistent with the findings of previous studies [17, 24, 27, 28] , we found that individuals with depressive symptoms were more likely to initiate psychotropic drug use. In addition, incident use was associated with lower MMSE scores, which may largely explain the high prevalence of psychotropic drug use among elderly people with dementia [2, 3] . Other characteristics associated with incident use included frequent visits to physician, moderate/poor self-rated health and moderate/poor life-satisfaction, suggesting that the initiation of psychotropic drugs is also related to physical morbidity, non-specific symptoms and drug seeking behavior. However, these associations may involve residual confounding by some unmeasured conditions, such as insomnia and anxiety.
In contrast to previous studies, we did not find a relationship between female gender and persistent [19, 22, 25] or incident use [24, 27, 28] of psychotropic drugs. Conflicting findings may result from differences in the drugs considered and participants' age as the majority of the previous studies focused on benzodiazepines and people aged≥65 years. In addition, some follow-up studies analyzed only those individuals who had survived until the end of the follow-up [19, 24] , potentially leading to over-representation of healthy men in a study population. Furthermore, some studies compared persistent users with never users [19, 23] ; consequently, their results may Participants with missing data on any of the chosen variables were excluded from the analyses (n=23). Missing GDS scores were imputed with the mean value for the whole study population a Cox proportional-hazards regression (adjusted for group assignment)
b Cox proportional-hazards regression (adjusted for group assignment and the other variables listed in the Table 5) reflect determinants of use in general, rather than persistent use. In fact, a number of studies have detected that female gender has minor influence on duration of psychotropic drug use among prevalent users [17, 20, 24] , supporting the findings of our study. In addition to the characteristics considered here, psychotropic drug use may be related to health system characteristics. For example, both incident and persistent use of benzodiazepines has been associated with a high number of prescribing physicians [22, 28] . The finding could partly explain the frequency of persistent use in Finland, where many different physicians are typically involved in each patient's care. In Finland, it is also common that physicians renew psychotropic prescriptions without meeting the patient [37] . Persistent use of psychotropic drugs may also arise from patient attitudes. Negative perceptions against discontinuation are typically attributed to fear of recurrence, feeling of being unable to manage without and underestimation of potential adverse effects [38] [39] [40] . On the other hand, primary care physicians may be pessimistic about successful discontinuation and encounter multiple barriers when trying to interfere in a patient's benzodiazepine use [41] .
Methodological considerations
The annually collected data used here provided a great opportunity to prospectively analyze longitudinal patterns of psychotropic drug use at an individual level. Furthermore, the self-reported data on drug use can be considered valid since the information was confirmed from the prescriptions, drug packages and medical records. In addition, the self-reported data was in agreement with the information extracted from the Finnish Prescription Register (includes reimbursable drugs dispensed in the Finnish community pharmacies) with κ values of 0.84 for antipsychotics, 0.88 for antidepressants and 0.70 for benzodiazepines [42] . A further advantage of the study was the fact that not only the survivors, but also those who were lost to followup during the study period were included in the analyses.
The study has some limitations. To begin with, the study may have overestimated the occurrence of persistent use (if a participant had a long gap in psychotropic drug use between the follow-ups) and underestimated the occurrence of both persistent use (if a participant happened to have a gap in psychotropic drug use at the time of the follow-up) and incident use (if a participant used psychotropic drug between the follow-ups). The study was further limited by the fact that at the beginning of the follow-up the sample of psychotropic drug users was a mixture of short-term and long-term users. Therefore, the characteristics of persistent users identified in this study may differ from those identified in a sample of new users [15, 26] .
Some additional limitations need to be considered regarding the Cox proportional-hazards regression analyses.
The study could not take into consideration some potential characteristics of persistent and incident users, such as insomnia and anxiety. In addition, the study used only baseline measurements for time-dependent variables. This may have biased the associations for variables with a tendency to vary over time, such as self-rated health and self-rated life satisfaction assessments. Nevertheless, the use of time-dependent Cox proportional-hazards regression was not considered appropriate because the potential variation in time-dependent variables may be affected by other variables included in the analyses [43] .
Conclusions
Psychotropic drugs, benzodiazepines in particular, are frequently used for extended periods by the communitydwelling individuals aged≥75 years. Individuals with multiple psychotropic drugs and a regular pattern of use are most susceptible to persistent use. Characteristics associated with incident use include depressive symptoms, cognitive decline and poor general health. Further research is needed to evaluate whether the characteristics of persistent and incident users vary between antipsychotics, antidepressants and benzodiazepines.
